Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre

The Lancet

Volumn 336, Issue 8717, 1990, Pages 709-711

  Cohen Tervaert, J W ^a   Huitema, M G ^a   Sluiter, W J ^a   The, T H ^a   van der Hem, G K ^a   Kallenberg, C G M ^a   Hene R J ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE ANTIBODY; PREDNISOLONE;

ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PREVENTION; PRIORITY JOURNAL; RELAPSE; WEGENER GRANULOMATOSIS;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; AUTOANTIBODIES; CYCLOPHOSPHAMIDE; CYTOPLASMIC GRANULES; DRUG EVALUATION; FEMALE; HUMAN; MALE; MIDDLE AGE; NEUTROPHILS; PREDNISOLONE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; WEGENER'S GRANULOMATOSIS;

EID: 0024999139     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(90)92205-V     Document Type: Article

References (28)

1. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years
2. Wegener's granulomatosis: observations on 18 patients with severe renal disease
3. Association between active Wegener's granulomatosis and anticytoplasmic antibodies
4. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic consideration
5. Infectious complications of cyclophosphamide treatment for vasculitis
6. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis
7. The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion of vision?
8. Autoantibodies to neutrophils and monocytes: a new tool for diagnosis and a marker of disease activity in Wegener's granulomatosis
9. Prospective study of radioimmunoassay for antibodies against neutrophil cyctoplasm in diagnosis of systemic vasculitis
10. Anticytoplasmic autoantibodies their immunodiagnostic value in Wegener's granulomatosis
11. Sequential antineutrophil cytoplasm antibody titres in the management of systemic vasculitis
12. Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration
13. Wegener's granulomatosis: long-term follow-up of patients treated with cyclophosphamide
14. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA
15. Anti-neutrophil cytoplasm antibodies 1988
16. Wegener's granulomatosis autoantibodies identify a novel diisopropyl-fluorophosphate-binding protein in the lysosomes of normal human neutrophils
17. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase
18. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognise an elastinolytic enzyme
19. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis
20. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis
21. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis
22. Predictive value of rises in anti-double stranded DNA antibody levels for disease exacerbation in systemic lupus erythematosus a long term prospective study
23. Relapses in Wegener's granulomatosis: the role of infection
24. Autoantibodies to myeloid lysosomal enzymes: new clues to vasculitis and glomerulonephritis
25. The role of the c-ANCA antigen in the pathogenesis of Wegener's granulomatosis A hypothesis based on both humoral and cellular mechanisms
26. Wegener's granulomatosis: observations on treatment with antimicrobial agents
27. Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis
28. Comment on the article by DeRemee